Glenmark Life Sciences (Mid Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Glenmark Life Sciences Limited |
|||
|
Price: ₹949.95 (-2.9%) | ||
| 52 Week Low: ₹676.50 52 Week High: ₹1,335.10 |
|||
| Market Capital: 13,088.97 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Glenmark Life Sciences Share Price Target For 2025
- 1.1.1: Glenmark Life Sciences Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Glenmark Life Sciences Share Price Target For 2026
- 1.2.1: Glenmark Life Sciences Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Glenmark Life Sciences Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Glenmark Life Sciences Brief Company Overview
- 4: Glenmark Life Sciences Financial Performance
- 4.0.1: Is Glenmark Life Sciences A Good Buy For Long Term?
Glenmark Life Sciences, a Mid Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 107.4% returns in 3-year with 19.2% profit margin, making it a potential Multibagger.
To predict the Glenmark Life Sciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Glenmark Life Sciences Share Price Target For 2025
The line chart displays the monthly closing prices of Glenmark Life Sciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glenmark Life Sciences shares in 2025, see the table below.
Glenmark Life Sciences Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1059.5 (+11.53%) | Price Action: 21 Feb 2025 High |
| 2025 Target 2 | 1048.05 (+10.32%) | Price Action: 06 Dec 2024 Low |
| 2025 Target 1 | 1037.05 (+9.16%) | Price Action: 13 Aug 2024 High |
| Current Price | 949.95 | Glenmark Life Sciences's share price as of 25 Feb 2025 |
| Stop Loss 1 | 910.0 (-4.21%) | Price Action: 01 Aug 2024 High |
| Stop Loss 2 | 900.2 (-5.24%) | Price Action: 09 Jul 2024 High |
| Stop Loss 3 | 888.95 (-6.43%) | Price Action: 05 Feb 2024 High |
Short-Term Technical Outlook
Current Technical Position: Glenmark Life Sciences is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹1070.86 serves as the nearest technical reference point.
Historical Returns: 3-month: -12.37% | 6-month: -9.76% | 1-year: +9.38%
Glenmark Life Sciences Share Price Target For 2026
The line chart displays the monthly closing prices of Glenmark Life Sciences with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glenmark Life Sciences shares in 2026, see the table below.
Glenmark Life Sciences Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1531.48 (+61.21%) | Fibonacci Extension Level 123.60% |
| 2026 Target 2 | 1504.88 (+58.41%) | Price Action: Chart |
| 2026 Target 1 | 1489.98 (+56.84%) | Fibonacci Extension Level 64.90% |
| Current Price | 949.95 | Glenmark Life Sciences's share price as of 25 Feb 2025 |
| Stop Loss 1 | 825.8 (-13.07%) | Price Action: 21 Jun 2024 Low |
| Stop Loss 2 | 817.1 (-13.99%) | Price Action: 18 May 2024 Low |
| Stop Loss 3 | 808.0 (-14.95%) | Price Action: 22 May 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Glenmark Life Sciences is currently trading at 41.5% of its 52-week range (₹676.5 - ₹1335.1).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +9.38% | 3-year: +107.39% | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Glenmark Life Sciences Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹949.95 | ||
| 2025 | ₹1,382.69 | +45.55% | ₹1,403.43 |
| 2026 | ₹1,895.89 | +37.11% | ₹1,924.33 |
| 2027 | ₹2,538.41 | +33.89% | ₹2,576.49 |
| 2028 | ₹3,055.24 | +20.36% | ₹3,101.07 |
| 2029 | ₹3,975.95 | +30.13% | ₹4,035.59 |
| 2030 | ₹5,212.52 | +31.1% | ₹5,290.71 |
| 2031 | ₹6,995.23 | +34.2% | ₹7,100.16 |
| 2032 | ₹8,815.93 | +26.02% | ₹8,948.17 |
| 2033 | ₹10,599.94 | +20.23% | ₹10,758.94 |
| 2034 | ₹12,634.27 | +19.19% | ₹12,823.78 |
| 2035 | ₹15,141.08 | +19.84% | ₹15,368.20 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Glenmark Life Sciences Brief Company Overview
Glenmark Life Sciences Limited: A Leader in Active Pharmaceutical Ingredients Incorporated in 2011, Glenmark Life Sciences Limited is a renowned player in the pharmaceutical industry. The company specializes in developing, manufacturing, and supplying non-commoditized...
active pharmaceutical ingredients for various chronic therapeutic areas. Glenmark Life Sciences Key Products: Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, Cilostazol, Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, Lacosamide, Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, Linagliptin, Etoricoxib, Lornoxicam, Zolmitriptan, Frovatriptan, Olaparib, Palbociclib, Enzalutamide, Ruxolitinib, Atovaquone, Adapalene Services: Contract development and manufacturing services Market Presence: Exports products to Europe, North America, Latin America, Japan, and internationally Glenmark Life Sciences is committed to providing high-quality products and services, meeting the evolving needs of the pharmaceutical industry.Glenmark Life Sciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 13,088.97 Crore | Market valuation of Glenmark Life Sciences's shares. |
| Revenue (TTM) | 2,204.89 Crore | Total revenue generated by Glenmark Life Sciences over the past twelve months. |
| Net Income (TTM) | +423.5 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +23.52% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +19.2% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-14.9% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-19.7% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.62 | Company's total debt divided by total shareholder equity. |
| Total Debt | 15.97 Crore | Sum of Glenmark Life Sciences's current & long-term financial obligations. |
| Total Cash | 446.29 Crore | Total amount of liquid funds available to Glenmark Life Sciences. |
| Beta | 0.16 | Beta is less than 1 indicating that the Glenmark Life Sciences's price is less volatile than the market. |
Is Glenmark Life Sciences A Good Buy For Long Term?
Glenmark Life Sciences, a mid-cap stock with a market capitalization of ₹13,088.97 crore, shows mixed signals for long-term investment. While its recent performance is impressive, with 12-month returns at 67.31% and a healthy profit margin of 19.2%, Q2 2024-25 figures reveal a 19.7% decrease in earnings year-on-year and a 14.9% revenue drop quarter-on-quarter. The low debt of ₹15.97 crore against a cash balance of ₹446.29 crore is positive. However, the lack of 3 and 5-year return data prevents a comprehensive long-term assessment. Considering the volatility, it's currently an average buy, requiring further analysis before a strong recommendation.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
